Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

Cited by (1,030)

Items 701–800 of 1,030

1. Practical outpatient management of worsening chronic heart failure
   Nicolas Girerd, Nathan Mewton, Jean‐Michel Tartière, Damien Guijarro, Patrick Jourdain M, Thibaud Damy, Nicolas Lamblin, Antoni Bayés‐Genís, Pierpaolo Pellicori, James L. Januzzi et al. · 2022 · European Journal of Heart Failure
2. Dapagliflozin attenuates diabetes-induced diastolic dysfunction and cardiac fibrosis by regulating SGK1 signaling
   Seul-Gee Lee, Darae Kim, Jung-Jae Lee, Hyunju Lee, Ro-kyung Moon, Yong‐Joon Lee, Seung‐Jun Lee, Oh‐Hyun Lee, Choongki Kim, Jaewon Oh et al. · 2022 · BMC Medicine
3. Cost-effectiveness of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction
   Jimmy Zheng, Justin T. Parizo, John A. Spertus, Paul A. Heidenreich, Alexander T. Sandhu · 2022 · JAMA Internal Medicine
4. Management of patients with heart failure and preserved ejection fraction
   Alicja Piadlo, Patricia C. Campbell · 2023 · Heart
5. Ertugliflozin for Functional Mitral Regurgitation Associated With Heart Failure: EFFORT Trial
   Duk‐Hyun Kang, Sung‐Ji Park, Sung‐Hee Shin, In‐Chang Hwang, Yeonyee Elizabeth Yoon, Hyung‐Kwan Kim, Mijin Kim, Min‐Seok Kim, Sung‐Cheol Yun, Jong‐Min Song et al. · 2024 · Circulation
6. Guideline-Directed Medical Therapy for Heart Failure does not Exist: A Non-Judgmental Framework for Describing the Level of Adherence to Evidence-Based Drug Treatments for Patients with a Reduced Ejection Fraction
   Milton Packer, Marco Metra · 2020 · European Journal of Heart Failure
7. Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study
   Moa Lugner, Naveed A. Sattar, Mervete Miftaraj, Jan Ekelund, Stefan Franzén, Ann‐Marie Svensson, Björn Eliasson · 2021 · Cardiovascular Diabetology
8. Obesity-Related Heart Failure with Preserved Ejection Fraction
   Tomonari Harada, Masaru Obokata · 2020 · Heart Failure Clinics
9. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis
   Takayoshi Kanie, Atsushi Mizuno, Yoshimitsu Takaoka, Takahiro Suzuki, Daisuke Yoneoka, Yuri Nishikawa, Wilson Wai San Tam, Jakub Morze, Andrzej Rynkiewicz, Yiqiao Xin et al. · 2021 · Cochrane Database of Systematic Reviews
10. Lower cardiorenal risk with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study
    Kåre I. Birkeland, Johan Bodegård, Amitava Banerjee, Dae Jung Kim, Anna Norhammar, Jan W. Eriksson, Marcus Thuresson, Suguru Okami, Kyoung Hwa Ha, Nils Kossack et al. · 2020 · Diabetes Obesity and Metabolism
11. Potential Therapeutic Effects of Sodium Glucose-linked Cotransporter 2 Inhibitors in Stroke
    Fatima Alzahra Al Hamed, Hazem Fathy Elewa · 2020 · Clinical Therapeutics
12. The diuretic effects of SGLT2 inhibitors: A comprehensive review of their specificities and their role in renal protection
    Pierre Delanaye, André Jacques Scheen · 2021 · Diabetes & Metabolism
13. SGLT2 Inhibitors: The Sweet Success for Kidneys
    Atit Dharia, Abid Ali Khan, Vikas S. Sridhar, David Z.I. Cherney · 2023 · Annual Review of Medicine
14. Sodium‐Glucose Cotransporter‐2 Inhibitors After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Population‐Based Investigation
    Osung Kwon, Jun‐Pyo Myong, Yunhee Lee, Yeon-Jik Choi, Jeong Eun Yi, Suk Min Seo, Sung-Won Jang, Pum Joon Kim, Jung‐Min Lee · 2023 · Journal of the American Heart Association
15. Dapagliflozin mitigates cellular stress and inflammation through PI3K/AKT pathway modulation in cardiomyocytes, aortic endothelial cells, and stem cell-derived β cells
    Fatmah R. Alsereidi, Zenith Khashim, Hezlin Marzook, Ahmed M. Al-Rawi, Tiana Salomon, Mahra K. Almansoori, Moustafa M. Madkour, Ahmed Mohamed Hamam, Mahmoud Mohammed Ramadan, Quinn P. Peterson et al. · 2024 · Cardiovascular Diabetology
16. The DAPA-HF Trial: A Momentous Victory in the War against Heart Failure
    Deepak L. Bhatt, Subodh Verma, Eugene Braunwald M. D · 2019 · Cell Metabolism
17. Comparing the Benefit of Novel Therapies Across Clinical Trials
    Javed Butler, Kevin Joseph Anstrom, Paul W. Armstrong, For the VICTORIA Study Group · 2020 · Circulation
18. Assessing the cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus: a comprehensive economic evaluation using clinical trial and real-world evidence
    McEwan, Phil, Bennett, Hayley, Khunti, Kamlesh, Wilding, John, Edmonds, Christopher, Thuresson, Marcus, Wittbrodt, Eric, Fenici, Peter, Kosiborod, Mikhail · 2020 · Diabetes, Obesity and Metabolism
19. Sodium-glucose cotransporter 2 inhibitors: extending the indication to non-diabetic kidney disease?
    Claire C. J. Dekkers, Ron T. Gansevoort · 2019 · Nephrology Dialysis Transplantation
20. Protective Effects of Sodium-Glucose Transporter 2 Inhibitors on Atrial Fibrillation and Atrial Flutter: A Systematic Review and Meta- Analysis of Randomized Placebo-Controlled Trials
    Daobo Li, Yingying Liu, Tesfaldet Habtemariam Hidru, Xiaolei Yang, Yunsong Wang, Cheng Chen, Ka Hou Christien Li, Yuqi Tang, Yushan Wei, Gary Tse et al. · 2021 · Frontiers in Endocrinology
21. Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial
    Carolyn S.P. Lam, João Pedro Ferreira, Egon Pfarr, David Sim, Hiroyuki Tsutsui, Stefan D. Anker, Javed Butler, Gerasimos S Filippatos, Stuart Pocock, Naveed A. Sattar et al. · 2021 · European Heart Journal
22. Imeglimin prevents heart failure with preserved ejection fraction by recovering the impaired unfolded protein response in mice subjected to cardiometabolic stress
    Hiroki Kitakata, Jin Endo, Shun Hashimoto, Erika Mizuno, Hidenori Moriyama, Kohsuke Shirakawa, Shinichi Goto, Yoshinori Katsumata, Keiichi Fukuda, Motoaki Sano · 2021 · Biochemical and Biophysical Research Communications
23. Cardiovascular risk reduction throughout GLP-1 receptor agonist and SGLT2 inhibitor modulation of epicardial fat
    Gianluca Iacobellis, Marco Giorgio Baroni · 2021 · Journal of Endocrinological Investigation
24. Reverse re-modelling chronic heart failure by reinstating heart rate variability
    Julia A. Shanks, Yonis Abukar, Nigel A. Lever, Mridula Pachen, Ian J. LeGrice, David J. Crossman, Alain Nogaret, Julian F. R. Paton, Rohit Ramchandra · 2022 · Basic Research in Cardiology
25. Mitochondria as Therapeutic Targets in Heart Failure
    Julia Schwemmlein, Christoph Maack, Edoardo Bertero · 2022 · Current Heart Failure Reports
26. Sodium–Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure
    Xinyu Zou, Qingyang Shi, Per Olav Vandvik, Gordon Henry Guyatt, Chim Choy Lang, Sameer Parpia, Si Wang, Arnav Agarwal, Yiling Zhou, Ye Zhu et al. · 2022 · Annals of Internal Medicine
27. Short‐term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction ( DAPA‐VO 2 ): a randomized clinical trial
    Patricia Palau, Martina Amiguet, Eloy Domínguez, Clara Sastre, Anna Mollar, Julia Seller, José Manuel García Pinilla, Ainoha Larumbe, Alfonso Valle, Juan José Gómez‐Doblas et al. · 2022 · European Journal of Heart Failure
28. Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid–Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout
    Jawad H. Butt, Kieran F. Docherty, Brian Lee Claggett, Akshay Suvas Desai, Magnus Petersson, Anna Maria Langkilde, Rudolf A. de Boer, Adrian F. Hernandez, Silvio E. Inzucchi, Mikhail Kosiborod et al. · 2023 · JAMA Cardiology
29. Impact of Geroscience on Therapeutic Strategies for Older Adults With Cardiovascular Disease
    Daniel E. Forman, George A. Kuchel, John C. Newman, James L. Kirkland, Elena Volpi, George E. Taffet, Nir Barzilai, Ambarish Pandey, Dalane W. Kitzman, Peter Libby et al. · 2023 · Journal of the American College of Cardiology
30. Sodium–Glucose Cotransporter-2 Inhibitors in Heart Failure: Potential Decongestive Mechanisms and Current Clinical Studies
    Jan Biegus, Marat Fudim, Husam M. Salah, Hiddo J.L. Heerspink, Adriaan A. Voors, Piotr P. Ponikowski · 2023 · European Journal of Heart Failure
31. Anabolic androgenic steroids and cardiomyopathy: an update
    Kahtan Fadah, Gokul Gopi, Ajay Lingireddy, Vanessa L. Blumer, Tracy A. DeWald, Robert John Mentz · 2023 · Frontiers in Cardiovascular Medicine
32. SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain
    Bartosz Rolek, Mateusz Haber, Magdalena Gajewska, Sylwester Rogula, Arkadiusz Pietrasik, Aleksandra Gąsecka · 2023 · Journal of Cardiovascular Development and Disease
33. SGLT2 inhibitors: Beyond glycemic control
    Irtiza Hasan, Tasnuva Rashid, Vishal Jaikaransingh, Charles Heilig, Emaad M. Abdel‐Rahman, Alaa S. Awad · 2024 · Journal of Clinical & Translational Endocrinology
34. Seated Pulmonary Artery Pressure Monitoring in Patients With Heart Failure
    Jason L. Guichard, Eric L. Bonno, Michael E. Nassif, Taiyeb M. Khumri, David Miranda, Orvar Jonsson, Hirak Shah, Tamás Alexy, GREGORY P. MACALUSO, James P. Sur et al. · 2024 · JACC Heart Failure
35. Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure
    David D. Berg, Siddharth M. Patel, Paul Michael Haller, Abby L. Cange, Michael G. Palazzolo, Andrea Bellavia, Julia Kuder, Akshay Suvas Desai, Silvio E. Inzucchi, John J.V. McMurray et al. · 2025 · Circulation
36. Prognostic value of arterial stiffness measurements in cardiovascular disease, diabetes, and its complications: The potential role of sodium‐glucose co‐transporter‐2 inhibitors
    Dimitrios Patoulias, Christodoulos E. Papadopoulos, Konstantinos Stavropoulos, Ioanna Zografou, Michael N. Doumas, Asterios I. Karagiannis · 2020 · Journal of Clinical Hypertension
37. The impact of SGLT2 inhibition on imaging markers of cardiac function: A systematic review and meta-analysis
    Panagiotis Theofilis, Alexios S. Antonopoulos, Themistoklis Katsimichas, Evangelos K. Oikonomou, Gerasimos Siasos, Constantina Aggeli, Konstantinos P Tsioufis, Dimitris Tousoulis · 2022 · Pharmacological Research
38. Canagliflozin Suppresses Atrial Remodeling in a Canine Atrial Fibrillation Model
    Ryo Nishinarita, Shinichi Niwano, Hiroe Niwano, Hironori K. Nakamura, Daiki Saito, Tetsuro Sato, Gen Matsuura, Yuki Arakawa, Shuhei Kobayashi, Yuki Shirakawa et al. · 2021 · Journal of the American Heart Association
39. Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial
    Charlotte C. van Ruiten, Mark M. Smits, Megan D. Kok, Erik H. Serné, Daniël H. van Raalte, Mark H.H. Kramer, Max Nieuwdorp, Richard G. IJzerman · 2022 · Cardiovascular Diabetology
40. 2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults
    G.B. John Mancini, Eileen O’Meara, Shelley R. Zieroth, Mathieu Bernier, ALICE Y.Y. CHENG, David Z.I. Cherney, Kim Alexander Connelly, Justin Adrian Ezekowitz, Ronald Goldenberg, Lawrence A. Leiter et al. · 2022 · Canadian Journal of Cardiology
41. Outcomes After Transcatheter Edge-to-Edge Mitral Valve Repair According to Mitral Regurgitation Etiology and Cardiac Remodeling
    Sung‐Han Yoon, Moody M. Makar, Saibal Kar, Tarun Chakravarty, Luke Steven Oakley, Navjot Sekhon, Keita Koseki, Mamoo Nakamura, Michèle A. Hamilton, Jignesh K. Patel et al. · 2022 · JACC: Cardiovascular Interventions
42. Mechanisms of SGLT2 Inhibitors in Heart Failure and Their Clinical Value
    Yafei Xie, Yujie Wei, Dan Li, Jie Pu, Hong Ding, Xiaowei Zhang · 2023 · Journal of Cardiovascular Pharmacology
43. Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
    Safia Chatur, Muthiah Vaduganathan, Brian Lee Claggett, Orly Vardeny, Akshay Suvas Desai, Pardeep S. Jhund, Rudolf A. de Boer, Carolyn S.P. Lam, Mikhail Kosiborod, Sanjiv Jayendra Shah et al. · 2023 · European Heart Journal
44. Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events
    Bertram Pitt, Deepak L. Bhatt, Michael J. Szarek, Christopher Paul Cannon, Lawrence A. Leiter, Darren K. McGuire, Julia Breyer Lewis, Matthew C. Riddle, Adriaan A. Voors, Marco Metra et al. · 2023 · JACC Heart Failure
45. Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart Failure
    Mikhail Kosiborod, David Z.I. Cherney, Akshay Suvas Desai, Jeffrey M. Testani, Subodh Verma, Khaja Chinnakondepalli, David I. Dolling, Shachi Patel, Magnus Dahl, James M. Eudicone et al. · 2024 · Journal of the American College of Cardiology
46. 2026 ESC Guidelines for the management of heart failure
    Lars Køber, Marianna Adamo, Anne‐Christine Ruwald, Daniela Tomasoni, Lisa Anderson, Charlotte Andersson, Jasper Jan Brugts, Ovidiu Dragomir Chioncel, Erwan Donal, Péter Ferdinandy et al. · 2026 · European Heart Journal
47. SGLT2 Inhibitors for Treatment of Refractory Hypomagnesemia: A Case Report of 3 Patients
    Evan C. Ray, Cary R. Boyd‐Shiwarski, Pengfei Liu, Danica Novacic, David M Cassiman · 2020 · Kidney Medicine
48. Prescribing in Type 2 Diabetes Patients With and Without Cardiovascular Disease History: A Descriptive Analysis in the UK CPRD
    Ruth E. Farmer, Ivan Beard, Syed I. Raza, Nicholas D. Gollop, Niraj Patel, Abigail Tebboth, Andrew Peter McGovern, Naresh Kanumilli, Andrew Ternouth · 2021 · Clinical Therapeutics
49. Multiple hormonal and metabolic deficiency syndrome predicts outcome in heart failure: the T.O.S.CA. Registry
    Antonio Cittadini, Andrea Salzano, Massimo Iacoviello, Vincenzo Triggiani, Giuseppe Rengo, Francesco Cacciatore, Ciro Maiello, Giuseppe Limongelli, Daniele Masarone, Francesco Perticone et al. · 2021 · European Journal of Preventive Cardiology
50. Combination pharmacotherapies for cardiac reverse remodeling in heart failure patients with reduced ejection fraction: A systematic review and network meta-analysis of randomized clinical trials
    Jieli Bao, Rongsheng Kan, Junhong Chen, Haochen Xuan, Chaofan Wang, Dongye Li, Tongda Xu · 2021 · Pharmacological Research
51. 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome
    Ndumele, Chiadi E., Rodriguez, Fatima, Dixon, Dave L., Khan, Sadiya S., Mukherjee, Debabrata, Bajaj, Mandeep, Bangalore, Sripal, Bozkurt, Biykem, Breathett, Khadijah, Clarke, Shoa L. et al. · 2026 · JACC
52. Sodium-glucose co-transporter-2 inhibitors and major adverse limb events: a trial-level meta-analysis including 51 713 individuals
    Huang, Chen‐Yu, Lee, Jen‐Kuang · 2020 · Diabetes, Obesity and Metabolism
53. Cost-utility analysis of add-on dapagliflozin treatment in heart failure with reduced ejection fraction
    Rungroj Krittayaphong, Unchalee Permsuwan · 2020 · International Journal of Cardiology
54. Dapagliflozin for Heart Failure with Preserved Ejection Fraction: Will the DELIVER Study Deliver?
    David M. Williams, Marc Evans · 2020 · Diabetes Therapy
55. SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies
    Annamaria Mascolo, Cristina Scavone, Lucia Scisciola, Paolo Chiodini, Annalisa Capuano, Giuseppe Paolisso · 2021 · Pharmacological Research
56. The role of hyperglycaemia in the development of diabetic cardiomyopathy
    Magali Samia El Hayek, Laura Ernande, Jean‐Pierre Bénitah, Ana Maria Gomez, Laëtitia Pereira · 2021 · Archives of cardiovascular diseases
57. Enhanced Expression and Function of Renal SGLT2 (Sodium-Glucose Cotransporter 2) in Heart Failure: Role of Renal Nerves
    Kenichi Katsurada, Shyam Sundar Nandi, Neeru M. Sharma, Kaushik P. Patel · 2021 · Circulation Heart Failure
58. Angiotensin–neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure
    Finnian R. Mc Causland, Martin P. Lefkowitz, Brian Lee Claggett, Milton Packer, Michele Senni, Mauro Gori, Pardeep S. Jhund, Martina M. McGrath, Jean Lucien Rouleau, Victor Chengwei Shi et al. · 2022 · European Journal of Heart Failure
59. Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: a secondary analysis of EMPEROR‐Reduced
    Gerasimos S Filippatos, Stefan D. Anker, Javed Butler, Dimitrios T. Farmakis, João Pedro Ferreira, Nicholas D. Gollop, Martina Brueckmann, Tomoko Iwata, Stuart Pocock, Faiez M. Zannad et al. · 2022 · European Journal of Heart Failure
60. Sodium–glucose co-transporter-2 inhibitors for the prevention of atrial fibrillation: a systemic review and meta-analysis
    Hongda Zhang, Lei Ding, Lijie Mi, Ai-Kai Zhang, Kuo Zhang, Zihan Jiang, Fengyuan Yu, Xin-Xin Yan, Yu-Jing Shen, Min Tang · 2023 · European Journal of Preventive Cardiology
61. Effect of Sodium-Glucose Cotransporter 2 Inhibitors in Adults With Congenital Heart Disease
    Ralph M.L. Neijenhuis, Simon Thomas MacDonald, Filip Zemrak, Bart J.A. Mertens, Anna Dinsdale, Amanda L. Hunter, Niki L. Walker, Lorna Swan, Sushma Reddy, Joris I. Rotmans et al. · 2024 · Journal of the American College of Cardiology
62. SGLT2i and Primary Prevention of Cancer Therapy–Related Cardiac Dysfunction in Patients With Diabetes
    Ammar W. Bhatti, Rushin P. Patel, Sourbha S. Dani, Sumanth Khadke, Bhargav Makwana, Candace Lessey, Jui Rakesh Shah, Zaid Husami, Eric H. Yang, Paaladinesh Thavendiranathan et al. · 2024 · JACC CardioOncology
63. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?
    Matthew M.Y. Lee, Mark Colquhoun Petrie, John J.V. McMurray, Naveed A. Sattar · 2020 · Arteriosclerosis Thrombosis and Vascular Biology
64. DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure
    Edgardo Kaplinsky · 2020 · Drugs in Context
65. Cost-Effectiveness of Adding Dapagliflozin to Standard Treatment for Heart Failure with Reduced Ejection Fraction Patients in China
    Younan Yao, Rongcheng Zhang, Tao An, Xinke Zhao, Jian Zhang · 2020 · ESC Heart Failure
66. Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care
    Wilfried Müllens, Angelo Auricchio, Pieter Martens, Klaus K. Witte, Martín Cowie, Victoria Delgado, Kenneth Dickstein, Cecilia Marianne Linde, Kevin Vernooy, Francisco Leyva et al. · 2020 · EP Europace
67. Diabetes mellitus type 2 in adults
    Ivan Ivanovich Dedov, Marina Vladimirovna Shestakova, Alexander Yu. Mayorov, Минара Шамхаловна Шамхалова, Olga Yu. Sukhareva, Gagik Radikovich Galstyan, Alla Yur'evna Tokmakova, Tatiana Vasil'evna Nikonova, Elena Viktorovna Surkova, Ирина Владимировна Кононенко et al. · 2020 · Diabetes Mellitus
68. Left Ventricular Hypertrophy: Etiology-Based Therapeutic Options
    Begüm Yetiş Sayın, Ali̇ Oto · 2022 · Cardiology and Therapy
69. Diabetes and Progression of Heart Failure
    Echouffo-Tcheugui, Justin B., Ndumele, Chiadi E., Zhang, Sui, Florido, Roberta, Matsushita, Kunihiro, Coresh, Josef, Skali, Hicham, Shah, Amil M., Selvin, Elizabeth · 2022 · Journal of the American College of Cardiology
70. Weight Change and Clinical Outcomes in Heart Failure with Reduced Ejection Fraction: Insights from EMPEROR-Reduced
    Stefan D. Anker, Muhammad Shahzeb Khan, Javed Butler, Anne Pernille Ofstad, Barbara Peil, Egon Pfarr, Wolfram Doehner, Naveed A. Sattar, Andrew J.S. Coats, Gerasimos S Filippatos et al. · 2022 · European Journal of Heart Failure
71. Changes in the use of glucose‐lowering drugs: A Danish nationwide study
    Anton Pottegård, Jacob Harbo Andersen, Jens Søndergaard, Reimar Wernich Thomsen, Tina Vilsbøll · 2022 · Diabetes Obesity and Metabolism
72. Impact of dapagliflozin on cardiac function following anterior myocardial infarction in non-diabetic patients – DACAMI (a randomized controlled clinical trial)
    Tarek Khairy Abdeldayem, Omar Younis, Bassem Zarif, Sameh Attia, Ahmed AbdelSalam · 2023 · International Journal of Cardiology
73. Research advances in the anti-inflammatory effects of SGLT inhibitors in type 2 diabetes mellitus
    Ruining Zhang, Qingxing Xie, Xi Lu, Rongping Fan, Nanwei Tong · 2024 · Diabetology & Metabolic Syndrome
74. The Use of Left Ventricular Ejection Fraction in the Diagnosis and Management of Heart Failure. A Clinical Consensus Statement of the Heart Failure Association (HFA) of the ESC, the Heart Failure Society of America (HFSA), and the Japanese Heart Failure Society (JHFS)
    Giuseppe M.C. Rosano, John R. Teerlink, Koichiro Kinugawa, Antoni Bayés‐Genís, Ovidiu Chioncel, James Chen-Tson Fang, Barry Greenberg, Nasrien E. Ibrahim, Teruhiko Imamura, Takayuki Inomata et al. · 2025 · European Journal of Heart Failure
75. Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials
    Faiez M. Zannad, Christopher M. O’Connor, Javed Butler, Ciaran J. McMullan, Kevin Joseph Anstrom, Irina Barash, Marc P. Bonaca, Maria Borentain, Stefano Corda, Davis F. Gates et al. · 2025 · The Lancet
76. Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty ( EMPRISE ) study
    Elisabetta Patorno, Ajinkya M Pawar, Deborah J. Wexler, Robert J. Glynn, Lily Gui Bessette, Julie M. Paik, Mehdi Najafzadeh, Kimberly Goodnow Brodovicz, Anouk Déruaz‐Luyet, Sebastian Schneeweiß · 2021 · Diabetes Obesity and Metabolism
77. Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline‐directed medical therapy in heart failure with reduced ejection fraction
    Petar M Seferovic, Marija M. Polovina, Christopher Adlbrecht, Jan Bělohlávek, Ovidiu Chioncel, Eva Gonçalvesová, Ivan Milinković, Avishay Grupper, Róbert Halmosi, Ginta Kamzola et al. · 2021 · European Journal of Heart Failure
78. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial
    Subodh Verma, Nitish K Dhingra, Javed Butler, Stefan D. Anker, João Pedro Ferreira, Gerasimos Filippatos, James L. Januzzi, Carolyn S.P. Lam, Naveed A. Sattar, Barbara Peil et al. · 2021 · The Lancet Diabetes & Endocrinology
79. NADPH Oxidases in Diastolic Dysfunction and Heart Failure with Preserved Ejection Fraction
    James P. Teuber, Kobina Essandoh, Scott L. Hummel, Nageswara R. Madamanchi, Matthew J. Brody · 2022 · Antioxidants
80. Recurrent Events in Cardiovascular Trials
    John Gregson, Gregg W. Stone, Deepak L. Bhatt, Milton Packer, Stefan D. Anker, Cordula Zeller, Björn Redfors, Stuart Pocock · 2023 · Journal of the American College of Cardiology
81. Chinese Guidelines for the Diagnosis and Treatment of Heart Failure 2024
    Shu-Yang ZHANG · 2025 · 老年心脏病学杂志：英文版
82. Mechano-energetic uncoupling in heart failure
    Dunja Aksentijević, Simon Sedej, Jérémy Fauconnier, Mélanie Paillard, Mahmoud Abdellatif, Katrin Streckfuß‐Bömeke, Renée Ventura‐Clapier, Jolanda van der Velden, Rudolf A. de Boer, Edoardo Bertero et al. · 2025 · Nature Reviews Cardiology
83. Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors
    Davide Margonato, Giuseppe Galati, Simone Mazzetti, Rosa Cannistraci, Gianluca Perseghin, Alberto Margonato, Andrea Mortara · 2020 · Heart Failure Reviews
84. Liraglutide as add-on to sodium-glucose co-transporter-2 inhibitors in patients with inadequately controlled type 2 diabetes: lIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial
    Blonde, Lawrence, Belousova, Lidia, Fainberg, Udi, Garcia‐Hernandez, Pedro A., Jain, Sunil M., Kaltoft, Margit S., Mosenzon, Ofri, Nafach, Jalal, Palle, Mads Sundby, Rea, Rosangela · 2020 · Diabetes, Obesity and Metabolism
85. Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update
    Salah, Husam M., Al'Aref, Subhi J., Khan, Muhammad Shahzeb, Al-Hawwas, Malek, Vallurupalli, Srikanth, Mehta, Jawahar L., Mounsey, J Paul, Greene, Stephen J., McGuire, Darren K., Lopes, Renato D. et al. · 2021 · American Heart Journal
86. Challenges in Promoting Health Equity and Reducing Disparities in Access Across New and Established Technologies
    Hoagland, Alex, Kipping, Sarah · 2024 · Canadian Journal of Cardiology
87. Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA‐HF
    Pooja Dewan, Kieran F. Docherty, Olof Bengtsson, Rudolf A. de Boer, Akshay Suvas Desai, Jarosław Dróżdż, Nathaniel Mark Hawkins, Silvio E. Inzucchi, Masafumi Kitakaze, Lars Køber et al. · 2020 · European Journal of Heart Failure
88. A Novel Approach to Medical Management of Heart Failure With Reduced Ejection Fraction
    Robert J.H. Miller, Jonathan G. Howlett, Nowell Mark Fine · 2021 · Canadian Journal of Cardiology
89. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial
    Jawad H. Butt, Carly Adamson, Kieran F. Docherty, Rudolf A. de Boer, Mark Colquhoun Petrie, Silvio E. Inzucchi, Mikhail N. Kosiborod, Anna Maria Langkilde, Daniel P. Lindholm, Felipe A. Martinez et al. · 2021 · Circulation Heart Failure
90. Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure with Reduced or Preserved Ejection Fraction: A Meta-Analysis
    Arjun K. Pandey, Nitish K. Dhingra, Makoto Hibino, Vijay Gupta, Subodh Verma · 2022 · ESC Heart Failure
91. Managing Heart Failure in Patients on Dialysis: State-of-the-Art Review.
    M. S. Khan, Aymen Ahmed, S. Greene, M. Fiuzat, M. Kittleson, J. Butler, G. Bakris, G. Fonarow · 2022 · Journal of Cardiac Failure
92. Canagliflozin Improves Myocardial Perfusion, Fibrosis, and Function in a Swine Model of Chronic Myocardial Ischemia
    Sharif A. Sabe, Cynthia Xu, Mohamed Sabra, Dwight Douglas Harris, Akshay Malhotra, Ahmed Aboulgheit, Madigan E. Stanley, Md. Ruhul Abid, Frank William Sellke · 2022 · Journal of the American Heart Association
93. Cardiovascular and renal effects of SGLT2 inhibitor initiation in acute heart failure: a meta-analysis of randomized controlled trials
    Pedro E P Carvalho, Thiago M. A. Veiga, Ana Cristina Simões e Silva, Douglas Mesadri Gewehr, Caroline Serafim Dagostin, Amanda Dantas Ferreira Fernandes, Guilherme Marmontel Nasi, Rhanderson N. Cardoso · 2023 · Clinical Research in Cardiology
94. Mapping the metabolic reprogramming induced by sodium-glucose cotransporter 2 inhibition
    Aviram Kogot‐Levin, Yael Riahi, Ifat Abramovich, Ofri Mosenzon, Bella Agranovich, Liat Kadosh, Rachel Ben‐Haroush Schyr, Doron Kleiman, Liad Hinden, Erol Cerasi et al. · 2023 · JCI Insight
95. SGLT1: A Potential Drug Target for Cardiovascular Disease
    Mengnan Zhao, Na Li, Hong Zhou · 2023 · Drug Design Development and Therapy
96. Vascular (dys)function in the failing heart
    Luca Liberale, Dirk Jan Duncker, Derek John Hausenloy, Simon C Kraler, Hans Erik Bøtker, Bruno Karl Podesser, Gerd Heusch, Petra Kleinbongard · 2025 · Nature Reviews Cardiology
97. Adjusted win ratio with stratification: Calculation methods and interpretation
    Samvel B. Gasparyan, Folke Folkvaljon, Olof Bengtsson, Joan Buenconsejo, Gary G. Koch · 2020 · Statistical Methods in Medical Research
98. Use of Sodium–Glucose Co-Transporter-2 Inhibitors in Patients with and without Type 2 Diabetes: Implications for Incident and Prevalent Heart Failure
    Javed Butler, Yehuda Handelsman, George L. Bakris, Subodh Verma · 2020 · European Journal of Heart Failure
99. Effects of an outpatient intervention comprising nurse‐led non‐invasive assessments, telemedicine support and remote cardiologists' decisions in patients with heart failure ( AMULET study): a randomised controlled trial
    Paweł Krzesiński, Ewa Anita Jankowska, Janusz Siebert, Agata Anna Galas, Katarzyna Piotrowicz, Adam Stańczyk, Paweł Siwołowski, Piotr G. Gutknecht, Paweł Chrom, Piotr Murawski et al. · 2021 · European Journal of Heart Failure
100. Repurposing Antidiabetic Drugs for Cardiovascular Disease
     Mario Schubert, Sinah Hansen, Julian Leefmann, Kaomei Guan · 2020 · Frontiers in Physiology